Akèy › Dematit atopik (Ekzema) › Arkansas
Etid klinik pou Dematit atopik (Ekzema) nan Arkansas
8 etid pou Dematit atopik (Ekzema) ap chèche patisipan nan sit nan Arkansas.
Vil nan Arkansas
Tèks ofisyèl etid la (Anglè)
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Fort Smith
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Hot Springs
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07298395A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Arkansas Research Trials, North Little Rock
Ap rekriteFaz 3
Laj 2 a 11 · Tout sèks · Mizajou Sep 25, 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Dermatology Trial Associates, Inc, Bryant
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Aug 28, 2026 · NCT07599813A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Applied Research Center and Wellness Clinic /ID# 268547, Little Rock
Ap rekriteFaz 3
Laj 2 a 11 · Tout sèks · Mizajou Aug 6, 2026 · NCT06461897A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, North Little Rock
Ap rekriteFaz 3
6 Months – 11 Years · Tout sèks · Mizajou Jul 7, 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville
Ap rekriteFaz 3
Laj 18 a 63 · Tout sèks · Mizajou Jul 6, 2026 · NCT06389136A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- Arkansas Research Trials, North Little Rock
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 19, 2025 · NCT06055361Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.